TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Rosen Law Firm
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following allegations of materially misleading business information. The investigation was triggered by Alvotech's November 2, 2025 announcement that the FDA issued a complete response letter for its AVT05 biologics license application, citing manufacturing deficiencies. The stock fell 34% on November 3, 2025, and the firm is preparing a class action lawsuit to recover investor losses.

Insights
ALVO   negative

The company received an FDA complete response letter indicating manufacturing deficiencies that must be resolved before approval of its AVT05 application. This regulatory setback caused a 34% stock price decline and triggered a securities investigation for allegedly issuing materially misleading information to investors.